Associations of TNF Variants, MHC Class II Alleles, and MHC Haplotypes in Patients With CA
| . | Allele or Haplotype . | Genotype Frequencies . | Pc Value . | |
|---|---|---|---|---|
| . | . | CA* Patients . | Controls . | . |
| Ashkenazi | HLA-DRB1*0402 | 11/24 | 6/54 | NS† |
| Jewish | HLA-DQB1*0302 | 11/24 | 8/54 | NS† |
| HLA-DQA1*0301 | 12/24 | 13/54 | NS† | |
| TNFd3 | 17/24 | 11/36 | .02 | |
| TNFb4 | 19/24 | 11/36 | .002 | |
| TNFb5 | 1/24 | 21/36 | .0005 | |
| [HLA-DRB1*0402, DRB4*0101, DQB1*0302, DQA1*0301, HSP70-2*A, HSP70-1*9, TNFe3, TNFd3, TNFα(−308)*1, TNFβn(A/G)*2, TNFa10, TNFb4, HLA-B38 ] | 12/24 | 3/36 | NS† | |
| Non-Jewish | HLA-DRB1*02 | 14/40 | 4/32 | NS† |
| HLA-DQB1*0502 | 10/40 | 1/32 | NS† | |
| HLA-DQA1*0102 | 15/40 | 3/32 | .04 | |
| TNFd3 | 34/42 | 17/30 | NS | |
| TNFb4 | 29/42 | 6/30 | .0005 | |
| TNFb5 | 8/42 | 22/30 | .0005 | |
| [HLA-DRB1*02+, DRB5*02, DQB1*0502, DQA1*0102, HSP70-2*A, HSP70-1*9, TNFe3, TNFd3, TNFα(−308)*1, TNFβn(A/G)*2, TNFa11, TNFb4] | 10/40 | 0/32 | NS† | |
| Combined | TNFd3 | 51/66 | 28/66 | .001 |
| TNFb4 | 48/66 | 17/66 | .0005 | |
| TNFb5 | 9/66 | 43/66 | .0005 | |
| [HLA-DRB1*0402, DRB4*0101, DQB1*0302, DQA1*0301, HSP70-2*A, HSP70-1*9, TNFe3, TNFd3, TNFα(−308)*1, TNFβn(A/G)*2, TNFa10, TNFb4, HLA-B38 ] | 12/64 | 4/66 | NS | |
| [HLA-DRB1*02 #, DRB5*02, DQB1*0502, DQA1*0102, HSP70-2*A, HSP70-1*9, TNFe3, TNFd3, TNFα(−308)*1, TNFβn(A/G)*2, TNFa11, TNFb4] | 10/64 | 0/66 | NS | |
| . | Allele or Haplotype . | Genotype Frequencies . | Pc Value . | |
|---|---|---|---|---|
| . | . | CA* Patients . | Controls . | . |
| Ashkenazi | HLA-DRB1*0402 | 11/24 | 6/54 | NS† |
| Jewish | HLA-DQB1*0302 | 11/24 | 8/54 | NS† |
| HLA-DQA1*0301 | 12/24 | 13/54 | NS† | |
| TNFd3 | 17/24 | 11/36 | .02 | |
| TNFb4 | 19/24 | 11/36 | .002 | |
| TNFb5 | 1/24 | 21/36 | .0005 | |
| [HLA-DRB1*0402, DRB4*0101, DQB1*0302, DQA1*0301, HSP70-2*A, HSP70-1*9, TNFe3, TNFd3, TNFα(−308)*1, TNFβn(A/G)*2, TNFa10, TNFb4, HLA-B38 ] | 12/24 | 3/36 | NS† | |
| Non-Jewish | HLA-DRB1*02 | 14/40 | 4/32 | NS† |
| HLA-DQB1*0502 | 10/40 | 1/32 | NS† | |
| HLA-DQA1*0102 | 15/40 | 3/32 | .04 | |
| TNFd3 | 34/42 | 17/30 | NS | |
| TNFb4 | 29/42 | 6/30 | .0005 | |
| TNFb5 | 8/42 | 22/30 | .0005 | |
| [HLA-DRB1*02+, DRB5*02, DQB1*0502, DQA1*0102, HSP70-2*A, HSP70-1*9, TNFe3, TNFd3, TNFα(−308)*1, TNFβn(A/G)*2, TNFa11, TNFb4] | 10/40 | 0/32 | NS† | |
| Combined | TNFd3 | 51/66 | 28/66 | .001 |
| TNFb4 | 48/66 | 17/66 | .0005 | |
| TNFb5 | 9/66 | 43/66 | .0005 | |
| [HLA-DRB1*0402, DRB4*0101, DQB1*0302, DQA1*0301, HSP70-2*A, HSP70-1*9, TNFe3, TNFd3, TNFα(−308)*1, TNFβn(A/G)*2, TNFa10, TNFb4, HLA-B38 ] | 12/64 | 4/66 | NS | |
| [HLA-DRB1*02 #, DRB5*02, DQB1*0502, DQA1*0102, HSP70-2*A, HSP70-1*9, TNFe3, TNFd3, TNFα(−308)*1, TNFβn(A/G)*2, TNFa11, TNFb4] | 10/64 | 0/66 | NS | |
The P values not corrected were as follows: Jewish: .02 for DRB1*0402, 0.008 for DQB1*0302, 0.003 for DQA1*0301, .02 for the haplotype; Non-Jewish: .03 for DRB1*02, .02 for DQB1*0502, .007 for DQA1*0102, .002 for the haplotype.
Abbreviations: NS, not significant; +, can be either *1501 or *1601.
Clozapine-induced agranulocytosis.
These P values were significant because they confirmed previous hypothesis based on pilot studies.45
Data from Yunis et al4 and Corzo et al.22